Non-activated macrophages express low levels of A 2A Rs and lipopolysaccharides (LPS) upregulates A 2A R expression in an NF-kBdependent manner. The murine A 2A R gene is encoded by three exons, m1, m2 and m3. Exons m2 and m3 are conserved, while m1 encodes the 5 0 untranslated UTR. Three m1 variants have been defined, m1A, m1B and m1C, with m1C being farthest from the transcriptional start site. LPS upregulates A 2A Rs in primary murine peritoneal and bone-marrow-derived macrophages and RAW264.7 cells by selectively splicing m1C to m2, through a promoter located upstream of m1C. We have cloned B1.6 kb upstream of m1C into pGL4.16(luc2CP/Hygro) promoterless vector. This construct in RAW 264.7 cells responds to LPS, and adenosine receptor agonists augmented LPS responsiveness. The NF-kB inhibitors BAY-11 and triptolide inhibited LPS-dependent induction. Deletion of a key proximal NF-kB site (402-417) abrogated LPS responsiveness, while deletion of distal NF-kB and C/EBPb sites did not. Sitedirected mutagenesis of CREB (309-320), STAT1 (526-531) and AP2 (566-569) sites had little effect on LPS and adenosine receptor agonist responsiveness; however, mutation of a second STAT1 site (582-588) abrogated this responsiveness. Further analysis of this promoter should provide valuable insights into regulation of A 2A R expression in macrophages in response to inflammatory stimuli.
INTRODUCTION
Macrophages have key roles in inflammation and wound repair, as innate immune cells that recognize, phagocytize and kill foreign organisms, debride dead and damaged cells and tissues, and as cells that secrete cytokines, growth factors and angiogenic factors that stimulate wound healing and angiogenesis. [1] [2] [3] Although there are resident populations of tissue macrophages, blood borne monocytes migrate to sites of injury or infection in response to chemo-attractants produced at these sites and differentiate into macrophages. In response to micro-environmental signals, these macrophages change their gene expression profile and become activated. Activation of macrophages with toll-like receptor (TLR) agonists such as LPS, either in the presence or absence of Interferon-g (IFNg), induces a 'classically' activated (M1) phenotype characterized by the expression of inflammatory cytokines, including TNFa, interleukin (IL)-1b, IL-12 and inducible nitric oxide synthase. [4] [5] [6] [7] [8] Activation with the Th2 cytokines IL-4 or IL-13 on the other hand, induces an 'alternatively' activated, anti-inflammatory phenotype that expresses low levels of TNFa and IL-12 and elevated levels of IL-10 and TGFb in an IL4Ra-dependent manner. 6, 7, [9] [10] [11] [12] [13] This represents the prototypical M2 phenotype, and has recently been termed 'M2a'. 14, 15 Other anti-inflammatory macrophage phenotypes have been described that are independent of IL4Ra signaling. 15, 16 We have described a pathway of induction of an anti-inflammatory, angiogenic macrophage phenotype that is induced by the synergistic action of TLR signaling together with adenosine A 2A receptor (A 2A R) signaling. [17] [18] [19] [20] [21] [22] This pathway switches macrophages from an inflammatory M1 phenotype to an angiogenic M2-like phenotype that we have termed 'M2d'. 23 The M2d macrophage is characterized by low levels of TNFa and IL-12, and high levels of vascular endothelial growth factor and IL-10 expression. Induction of the M2d phenotype involves the strong TLR-dependent induction of A 2A R expression, thereby priming the cells to respond to A 2A R agonists, which switch the cells to the M2d phenotype. 21, 24 The induction of A 2A R expression by TLR agonists such as LPS is transcriptionally regulated and NF-kB dependent. 21, 24 The murine A 2A R gene is encoded by three exons, m1, m2 and m3. 25 Exons m2 and m3 are conserved coding sequences, while the m1 exon codes for the 5 0 untranslated UTR. Three variants of the m1 exon have been defined, m1A, m1B and m1C. These variants are each encoded by different exons that are located at various distances upstream of the translational start site (Figures 1a and b) . The m1A exon is closest to the ATG translational start site, and the m1B and m1C exons are farther upstream. Prior studies have shown that exon m1A is detected only in brain, while exon m1C is most abundant in spleen and thymus. 25 In this study, we have examined the specific isoforms of A 2A Rs that are induced in primary murine peritoneal and bone marrow-derived macrophages in response to LPS stimulation. We show that the m1C exon is preferentially selected for splicing to the m2 coding exon, clearly indicating that the promoter for this induction must lie upstream of m1C. We have cloned the B1.6 kb sequence that lies upstream of the m1C exon into the pGL4.16(luc2CP/Hygro) promoterless vector (Promega Inc, Madison, WI, USA) to create a luciferase reporter plasmid for this LPS-inducible A 2A R isoform, and demonstrate here its LPS inducibility and NF-kB dependence.
RESULTS
A 2A R mRNA isoforms expressed by murine macrophages We have shown previously that LPS strongly induces the expression of A 2A R mRNA by murine macrophages. 21 Quantitative real-time PCR analysis of mRNA steady state levels showed that A 2A R mRNA levels are induced 20-40-fold at 2, 4 and 8 h following LPS stimulation, and then decrease to basal levels by 18-24 h. mRNA from LPS-treated peritoneal and bone marrowderived macrophages at 2, 4 and 8 h was converted to complementary DNA and analyzed for m1A, m1B and m1C exon isoforms by PCR using exon specific primers. The m1C isoform was the predominant isoform present at all time points, while the m1A and m1B isoforms were only weakly expressed (Figures 1c and d) . This indicates clearly that the m1C isoform is the preferred exon expressed following LPS stimulation of macrophages. This result strongly suggests that the LPS-inducible promoter in macrophages is upstream of the m1C exon in the genomic structure.
Cloning of the A 2A R m1C exon upstream promoter We used the Genome Walker Kit (Clontech Inc, Mountain View, CA, USA) to clone the 5 0 sequence upstream of the m1C exon using genomic DNA. DNA was individually digested with Dra1, StuI, PvuII and EcoRV as supplied with the kit, to generate blunt-end 'DNA libraries'. These libraries were designated DL1, DL2, DL3 and DL4, respectively. These libraries were subjected to PCR using iProof High Fidelity DNA polymerase (BioRad Inc, Hercules, CA, USA) with GC5x buffer supplied with the kit. The primers used for this step were constructed according to Genome Walker instructions with Adapter Primer 1 from the kit as upper primer, and a reverse primer, designated as GSP1, in the A 2A R exon m1C. The primer sequences were as follows:
Adapter 
DL1
, DL2 and DL3 each generated single PCR products, which were cloned into the pGL4.16 (luc2CP/Hygro) promoterless vector. The sequences of these amplicons were determined and are shown in Figure 2 . The largest amplicon (1655 bp) was from the DL2 library; the DL1 amplicon was 927 bp and the DL3 amplicon was 461 bp (Figure 2b ). These plasmids were used to study induction of luciferase expression following transient transfection of RAW264.7 cells. The plasmid containing the DL2 amplicon was designated as pGL4A 2A RlucDL2.
Transient transfection of RAW264.7 cells with pGL4A 2A Rluc RAW264.7 cells were transiently transfected with pGL4A 2A Rluc-DL2, followed by treatment with LPS or R848 for 6 h. Luciferase expression was then determined and compared with that of untreated cells (Figures 3a and b) . LPS strongly upregulated luciferase expression (410-fold; Figure 3a) . The non-specific adenosine receptor agonist 5 0 -N-ethylcarboxamidoadenosine (NECA) alone had little effect, but NECA strongly promoted the stimulatory effect of LPS. Similarly, R848 strongly induced luciferase expression and NECA and CGS21680 amplified this effect (Figure 3b ). Hypoxia (1% O 2 ) alone did not promote luciferase expression (data not shown). The NF-kB inhibitors BAY-11 (5 mM) and triptolide (20 mg ml À 1 ) strongly inhibited LPS-induced luciferase expression, suggesting an important role for NF-kB in this induction (Figure 3a ). SB203580 (a p38 MAPKinase inhibitor)(10 mM) also strongly inhibited luciferase expression, while U0126 (MEK1 and 2 inhibitor)(10 mM)and PD98059 (MEK1/MAPKK inhibitor)(10 mM) had little effect, suggesting an important role for p38 MAPK. The DL1 construct in pGL4.16(luc2CP/Hygro) showed similar responsiveness to LPS and NECA as the DL2 construct. DL3 showed a slightly attenuated response, but the pattern of responsiveness to LPS, NECA and LPS/NECA was similar to that of DL2 and DL1 (Figure 3c ).
Transient transfection of RAW264.7 cells with pGL4A 2A Rlu cDL2 with deletions of an NF-kB or a C/EBPb binding site The putative C/EBPb and NF-kB binding sites at positions 1342-1354 and 402-417 in the DL2 sequence in pGL4A 2A Rluc-DL2 were separately deleted using inverse PCR. The deletion plasmids (pGL4A 2A RlucDL2-C/EBPb and pGL4A 2A RlucDL2-NF-kB) were then transfected into RAW264.7 cells as described above, followed by treatment with LPS, NECA, CGS21680, and various inhibitors for 6 h. Deletion of the C/EBPb site had no significant ) for 4 h, mRNA was isolated and analyzed for m1 variants using specific PCR primers, as described in the Methods section. (d) m1 exons expressed in LPS-treated bone marrow-derived murine macrophages. Macrophages were treated as described in (c) above.
effect on the inducibility of the promoter; deletion of the NF-kB site however, strongly decreased responsiveness of the construct to both LPS and LPS/NECA (Figure 3b ).
Transient transfection of RAW264.7 cells with pGL4A 2A Rluc-DL1 with deletions of CREB/AP-1, STAT1 and AP-2 binding sites The putative CREB/AP1, STAT1 and AP2 sites at positions 309-320, 526-531 and 566-569 upstream of exon m1C in the DL1 sequence in pGL4A 2A Rluc-DL1 were individually deleted using the GENEART Site-Directed Mutagenesis System. The deletion plasmids (pGL4A 2A RlucDL1-CREB, pGL4A 2A RlucDL1-STAT1(566-569) and pGL4A 2A RlucDL1-AP2) were then transfected into RAW264.7 cells and treated as described above. Deletion of these CREB, STAT1 and AP2 did not significantly affect the responsiveness of these constructs to LPS or to the adenosine receptor agonist NECA ( Figure 4 ). In contrast, deletion of the putative STAT1 site located at position 582-588 abrogated responsiveness of the construct to both LPS and LPS/NECA ( Figure 4 ).
DISCUSSION
Macrophages have important roles in innate immunity and wound repair. Resting macrophages do not express significant levels of cytokines and growth factors such as TNFa, IL-1b and vascular endothelial growth factor. Stimulation of macrophages with TLR agonists such as LPS (TLR4 agonist) induces 'classical' activation, characterized by the upregulation of inflammatory cytokine expression, including TNFa, IL-1b, IL-12p70 and IL-6, and the inducible nitric oxide synthase. These macrophages express an inflammatory phenotype that has been termed 'M1'. 6, 14, 15, 26 M1 macrophages prime the inflammatory response, and participate in recognition, phagocytosis and killing of foreign organism, thus protecting sites of injury from invasion and infection. In contrast, macrophages can be activated by non-classical pathways to induce anti-inflammatory, wound healing phenotypes. 9, 10, 27, 28 Activation with IL-4 or IL-13 by signaling through the IL-4Ra, a subunit common to both the IL-4R and IL-13Rs, induces an 'alternatively activated' phenotype characterized by low expression of TNFa, IL-12 and inducible nitric oxide synthase, high expression of arginase, YM1 and FIZZ, and moderate expression of IL-10 and TGFb. These IL-4Ra-dependent macrophages have recently been termed 'M2a' macrophages. 15 We have defined a different pathway of macrophage activation that depends upon the synergistic action of TLR agonists with adenosine A 2A R agonists, and results in a phenotype characterized by low expression of TNFa and IL-12, and strongly elevated expression of IL-10 and vascular endothelial growth factor. 18, 20, 21, 23, 29 We have referred to this activation pathway as an 'angiogenic switch', 18 and have termed macrophages activated in this way as 'M2d'. 23 A key step in the induction of the M2d phenotype is the strong transcriptional upregulation of A 2A Rs by LPS in an NF-kB dependent manner. 21, 24 This upregulation of A 2A Rs primes macrophages to respond to adenosine, which is normally present extracellularly at low (nM) levels, but increases dramatically to micromolar levels as a result of breakdown of ATP in response to cell stress. 30, 31 Release of adenosine is dependent on the metabolic state of cells. Increased oxygen consumption or decreased oxygen supply lead to enhanced adenosine production. [31] [32] [33] We postulate that macrophages are primed by TLR agonists to respond to the presence of elevated extracellular adenosine by increasing their expression of A 2A Rs.
In the study reported here, we examined the induction of A 2A R expression in primary murine peritoneal and bone marrowderived macrophages in response to LPS. First, we show that the selection of exons for the production of the mRNA coding for A 2A R expression involves the selection of the m1C variant of exon m1. Three variants of the m1 exon have been defined, m1A, m1B and m1C. 25 These variants are each encoded by different exons that are located at various distances upstream of the translational start site. The m1A exon is closest to the ATG translational start site, and the m1B and m1C exons are farther upstream. Selection of the m1 exon is cell and tissue dependent. Prior studies have shown that exon m1A was detected only in brain, while exon m1C was most abundant in spleen and thymus. 25 As the m1C exon is farthest from the translational start site in exon 2, this data indicates that the promoter that mediates the LPS-dependent upregulation of transcription of this mRNA transcript must lie upstream of the m1C exon. Prior studies of the promoters for the A 2A R gene are sparse. Lee et al.
34-36 characterized a 4.8 kb 5 0 flanking region of the rat A 2A R. This region was located upstream of the m2 coding exon, and its relevance to the regulation of the transcript which includes the m1C exon is unclear. As shown clearly by Yu et al., 37 the m1C exon is located 8639 bp upstream of exon m2, while exons m1A and m1B are located much closer to m2, namely 749 and 932 bp upstream, respectively. The 4.8 kb rat fragment identified by Lee et al. 36 is thus likely to be most relevant for the expression of the transcript containing the m1A isoform, which is predominantly expressed in the central nervous system, but not in myeloid cells. Indeed, the expression analysis reported by Lee et al. 36 indicates that the 4.8 kb fragment containing the putative promoter regions regulated A 2A R expression only in the central nervous system. The molecular and bioinformatic analysis of the genomic organization of murine adenosine A 2A Rs provided by Yu et al. 37 indicates clearly that the A 2A R coding sequences are found in exons m2 and m3, and that three alternative non coding exons (m1A, m1B and m1C) are selectively spliced to the m2 exon during transcription. These studies also showed that the m1A exon was detected only in brain, while the m1C exon was expressed in all tissues examined, with greatest abundance in spleen and thymus. These results support the concept that alternative promoters are used for the expression of A 2A R mRNA in the brain (using the m1A exon) vs lymphoreticular tissues (using the m1C exon).
As the m1C exon is the most distal of the m1 exons, lying 8639 bp upstream of exon m2, we cloned an B1.6 kb region lying immediately upstream of the m1C exon into the pGL4.16(luc2 CP/ Hygro) promoterless vector to study the functionality of this region in the regulation of A 2A R expression. As shown in Figure 3 , the pGL4A 2A Rluc plasmid containing this putative promoter region responded strongly to the TLR4 agonist LPS when transfected into RAW264.7 macrophages. Both BAY-11 and triptolide, specific inhibitors of NF-kB activation, inhibited the LPS-induced stimulation. The p38 MAPK inhibitor SB203580 also inhibited LPS-induced luciferase expression, while the MAPKK inhibitor PD98059 and the MEK1 and 2 inhibitor U0126 did not. Similar results were obtained with the TLR7 agonist R848.
Bioinformatic sequence analysis indicated two putative NF-kB sites, a C/EBPb site, and two CREB sites within the DL2 region, as well as two STAT1 sites, NF-1, STAT3, HIF1, SP1 and AP1 sites and a CpG island close to the m1C-m2 exon interface (Figure 2) . The non-selective adenosine receptor agonist NECA and the A 2A R specific agonist CGS21680 had little effect alone on the expression of luciferase when RAW264.7 cells were transiently transfected with pGL4A 2A Rluc, but markedly increased the stimulatory effect of LPS. These effects were maintained in the DL1 deletion construct, which lacks the putative C/EBPb site in the DL2 construct. The DL1 and DL3 constructs also lack the most distal NF-kB, CREB and C/EBPb sites, but still respond to LPS, NECA and CGS21680 stimulation. This suggests that these sites are not critical for the LPS or LPS/NECA responses, and that the relevant regulatory sites are located closer to the m1C exon. The DL2 construct with a specific deletion of the proximal NF-kB site (402-417) did not respond to LPS or LPS/NECA, indicating that this NF-kB site has a key role in the response of the promoter to LPS. In addition, the DL1 construct with a specific deletion of the STAT1 site located at position 582-588 did not respond to LPS or LPS/NECA, indicating that this STAT1 site also has an important role in the response of this promoter to LPS. In contrast, site directed mutagenesis of other distinct CREB, STAT1 and AP2 sites in the DL1 construct had little effect on either the LPS-inducibility or the adenosine receptor agonist-dependent amplification of LPS-inducibility. Although there is a putative HIF1 binding site located at position 1621-1605, RAW264 cells transfected with pGL4A 2A Rluc did not express luciferase in response to hypoxia. This correlates well with previous data indicating that hypoxia alone does not induce A 2A R expression in murine macrophages. 22 Further studies are required to determine the specific requirements for individual transcription factor binding sites in this promoter region in the regulation of A 2A R expression by macrophages.
MATERIALS AND METHODS Reagents
NECA, 2-p-(2-carboxyethyl) phenethyl-amino-5 0 -N-ethyl-carboxamidoadenosine (CGS21680), U0126, PD98059, SB203580 and tryptolide were purchased from Sigma Chemical Co. (St Louis, MO, USA). Bay 11-7085 was purchased from Axxora, LLC (San Diego, CA, USA). Purified Escherichia coli LPS free of TLR2 agonists was a gift of Dr Stefanie Vogel (University of Maryland, College Park, MD, USA). R848 was purchased from InVivoGen (San Diego, CA, USA).
Animals
C57Bl/6J mice (female, 7-8 weeks) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). The animal experimentation protocols were approved by the NJMS Animal Care and Use Committee (Newark, NJ, USA).
Cell culture
Murine peritoneal macrophages were harvested from C57Bl/6J mice (7-8 weeks) as described previously. 20, 29, 38 Bone marrow-derived macrophages were prepared from hind limb femurs and tibiae of C57Bl/6J mice as described previously, 39 Bone marrow cells were differentiated for 8 days in DMEM/F12 medium supplemented with 10 mM L-glutamine, 100 IU ml À 1 penicillin, 100 mg ml À 1 streptomycin and 20% (v/v) L-929 cell conditioned medium as a source of M-CSF. The resultant differentiated macrophages were then harvested and replated as described below. RAW 264.7 (murine macrophage-like cell line) cells were purchased from American Type Culture Collection (Manassas, VA, USA). The cells were cultured as a monolayer in RPMI-1640 medium (Cellgro, Mediatech Inc, Herndon, VA, USA) supplemented with 10% fetal bovine serum (Gemini Bio-Products, Calabasas, CA, USA), 2 mM L-glutamine, 100 IU ml À 1 penicillin, and 100 mg ml À 1 streptomycin (Irvine Scientific, Santa Ana, CA, USA). All experiments were performed at a density of 1 Â 10 6 cells per ml medium. Cells were plated 20-24 h before stimulation. The medium used for stimulation contained 1% fetal bovine serum, and cells were stimulated with LPS (100 ng ml À 1 ), NECA (1 mM), CGS21680 (100 ng ml
), a combination of LPS and NECA, or LPS and CGS21680. For incubation of cells under hypoxic conditions, cultures were placed in a hypoxia chamber (BillupsRothenberg, Del Mar, CA, USA), which was filled with a gas mixture of 1% O 2 , 5% CO 2 and 94% N 2 . The sealed chamber was then placed in a 37 1C incubator and incubated overnight.
Extraction of RNA and quantitative real-time PCR
Mouse peritoneal macrophages and mouse bone marrow-derived macrophages were plated in 60 mm dishes (4 Â 10 6 cells/dish). Following overnight incubation, cells were treated with various reagents as indicated in the figure legends. RNA was isolated using Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA), according to the manufacturer's protocol for isolation of total RNA from animal cells. Complementary DNA was synthesized from 1 mg total RNA using TaqMan RT reagents (Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions. 
Analysis of A 2A R mRNA isoforms
Complementary DNA prepared from macrophages treated with LPS for 4 and 8 h as described above was analyzed by PCR. The sequences of the primers used to amplify the spliced isoforms were as reported previously by Yu et al. 25 A downstream reverse primer in the m2 exon (Primer m2R3) and upstream forward primers specific for the m1A, m1B and m1C exons (Primers m1A1, m1B1, m1C1, respectively) were used. All primers were used at a final concentration of 20 mM. PCR was performed as follows: preamplification at 98 1C for 1 min., followed by 35 cycles of 98 1C for 10 s, 62 1C for 30 s and 72 1C for 30 s. Samples were then incubated for 5 min at 72 1C, then kept at 4 1C. The PCR products were analyzed by electrophoresis on 4% agarose gels Cloning of the A 2A R m1C exon upstream promoter Genomic DNA was isolated from C57BL/6J wild-type mouse liver using the Stratagene Blood and Tissue Kit (Agilent Inc, La Jolla, CA, USA). DNA quality was checked by digestion with Dra1 at 37 1C overnight followed by electrophoresis on an 0.6% agarose gel, to determine that a high molecular weight single band with no degradation smear was obtained. The A 2A R promoter upstream of the m1C exon was cloned using the Genome Walker Kit (Clontech Inc, Mountain View, CA, USA). Genomic DNA was individually digested with Dra1, StuI, PvuII and EcoRV as supplied with the kit, to generate blunt-end 'DNA libraries'. A first round PCR of these libraries was performed using iProof High Fidelity DNA polymerase (BioRad Labs., Hercules, CA, USA) with GC5X Buffer supplied with the Genome Walker kit. The primers used for this step were constructed according to the Genome Walker kit instructions, with Adapter Primer 1 from the kit as the upper primer and the A 2A R exon m1C reverse primer, designated as GSP1, as the lower primer. Primers were used at 0.5 mM final concentration in the PCR mix. The sequence of the GSP1 primer was obtained from Gene Bank (Accession no. NM_009630), as follows: 5 0 -ggcgggaaccagggaaactgtctct-3 0 . The PCR conditions used were as follows: 98 1C preamplification for 1 min followed 7 cycles of 98 1C for 10 s; 72 1C for 3 min. This was followed by 37 PCR cycles as follows: 98 1C for 10 min; 67 1C for 1 min; 72 1C for 2 min, followed by a final extension at 72 1C for 10 min and cooling to 4 1C. A second PCR amplification round using nested primers was then performed. Adapter Primer 2 from the Genome Walker kit was used as the upper nested primer, and A 2A R exon m1C primer designated as GSP2 was used as the reverse nested primer. The sequence of the GSP2 primer was: 5 0 -CGAGGTGGTGATGGGTCCGGCAGCAAA-3 0 . All four libraries yielded a single major amplicon following PCR. These PCR amplicons were sequenced in the New Jersey Medical School Molecular Resources Facility by capillary electrophoresis using an ABI 3130XL Genetic Analyzer. The GSP1 primer listed above was used as the sequencing primer. The DL2 library yielded the longest fragment (B1.6 kB). All three fragments were then cloned into the pGL4.16(luc 2CP/Hygro) promoterless vector (Promega Inc, Madison, WI, USA). For this purpose, a Hind III restriction site was added to the 5 0 -end of GSP2 primer, and an Xho1 restriction site was added to 5 0 -end of Adapter Primer 2. PCR was then repeated using this set of primers and 1:50 dilution of the DL2 PCR material. The new bands were gel purified and cloned into the plasmid.
Deletion of putative NF-kB and C/EBPb sites by inverse PCR Using TransFac Patch bio-informatic analysis, a putative NF-kB binding site (GGGAATCTCC) was identified at position 402-417 upstream of the exon m1C start site in the DL2 promoter sequence, and a putative C/EBPb site (TTTGCCAAAGGG) was identified at position 1342-1354. To delete each of these sites individually, we performed inverse PCR using the pGL4.16(luc2CP/Hygro) vector containing the DL2 promoter sequence. Tail-to-tail primers were designed with an NdeI restriction site at their Site directed mutagenesis of putative CREB, STAT1 and AP2 binding sites Using TransFac Patch bio-informatic analysis, putative binding sites for CRE (ggggaggaGTCA), STAT1 (gaAAGG), a second STAT1 (ctTTCC) and for AP2 (GCCT) were identified at positions 309-320, 526-531, 582-588 and 566-569, respectively in the pGL4A 2A RDL1luc promoter sequence upstream from the start of exon m1c. Mutations of these sites were prepared using the GENEART Site-Directed Mutagenesis System from Invitrogen Life Technologies following the manufacturer's protocol. For the first STAT1 mutation, a 6 bp deletion of the core sequence was prepared in the DL1 construct. For the second STAT1 mutation, a 6 bp deletion of the core sequence was prepared. For the AP2 mutation, a 4 bp deletion of the core sequence was prepared. For the CRE deletion, a 12 bp deletion including the core GTCA sequence was prepared.
The primers used for the preparation of these deletions were as follows: STAT1 (526-531) binding site including 6 bp core sequence deletion in DL1 construct:
Upper strand: The reverse primers on the lower strand were 100% complementary to the forward primers.
Transient transfections and reporter assays
Plasmids were prepared using the PhoenIX Midiprep kit (Qbiogene, Carlsbad, CA, USA) and were electrophoresed to confirm that they were in the supercoiled form. RAW 264.7 cells were transiently transfected using Superfect (Qiagen, Valencia, CA, USA) as described previously 37. Cells were co-transfected with phRL-TK (Promega Corp.) to normalize for transfection efficiency. Following 18 h incubation, the transfectants were resuspended in fresh medium and plated into six-well plates at a density of 0.625 Â 10 6 cells per well, which were allowed to adhere for 6-7 h at 37 1C. The medium was then changed to RPMI 1640 with 1% fetal bovine serum, and the cells were stimulated as follows: LPS (100 ng ml À 1 ), NECA (1 mM), LPS/NECA, or hypoxia. Following 22 h incubation, cells were lysed with passive lysis buffer (Promega Corp.), and luciferase assays were performed using the dual-luciferase assay kit (Promega Corp.) following the manufacturer's protocol. Luciferase light units were measured using a SpectraMax L luminometer (Molecular Devices, Sunnyvale, CA, USA), with a dual injector system. Firefly luciferase light units were normalized to Renilla luciferase light units to normalize for transfection efficiency. The results reported are representative of at least three independent experiments.
Statistical analyses
Differences between groups were analyzed by the unpaired Student's t-test or one-way analysis of variance followed by Dunnett's test, as appropriate, by using the statistical analysis programs in KaleidaGraph software (Synergy Software, Reading, PA, USA). Values in the Figures are expressed as means±s.e.m.
